3.1.10.1. calcineurin inhibitors. cyclosporine tacrolimus significant side effects hazardous graft patient [243-250]. importantly, nephrotoxic , long-term use important cause chronic allograft dysfunction , eventually leading graft loss severe chronic kidney disease recipients non-renal organs. cnis considered ‘critical-dose‘ drugs, deviations exposure lead severe toxicity failure efficacy. narrow therapeutic window potential drug-to-drug interaction, cnis monitored using trough levels, provide reasonable estimate exposure . meta-analysis tacrolimus cyclosporine demonstrated similar outcomes respect overall patient graft survival [243-249,254-256]. tacrolimus provided better rejection prophylaxis associated better graft survival, censored death analyses. renal function favourable tacrolimus treated patients, number number trials [254,257-261]. therefore, cnis used effective prevention acute rejection, due higher efficacy tacrolimus recommended current guidelines first-line cni . cnis several different formulations available [250,262-270]. tacrolimus once-daily dosing seems preferred patients associated better adherence lower pharmacokinetic variability . precautions (e.g. close surveillance determination drug levels) instituted conversion one formulation another [270,273-277]. case specific side effects cni (e.g. hirsutism, alopecia, gingival hyperplasia, diabetes, polyoma nephropathy) conversion another cni successful strategy reduce side effects [243-245,278]. due differences efficacy safety profile, choice cni include individual risks benefits patient. despite side effects, cnis cornerstone modern immunosuppressive regimens thirty years resulted exemplary improvement kidney graft survival . future protocols aim minimise even eliminate cnis [245,248,250,279-282]. however, strategies provide superior outcomes, cnis remain standard care . severe cni-related side effects, cni withdrawal, replacement, profound reduction may needed . special attention paid maintenance patients, may need less cnis previously thought . summary evidencelemeta-analysis tacrolimus cyclosporine demonstrated similar outcomes respect overall patient graft survival however, tacrolimus provided better rejection prophylaxis renal function.1adue differences efficacy safety profile, choice cni take account immunological risk, characteristics, concomitant immunosuppression, socio-economic factors recipient.1 recommendationsstrength ratinguse calcineurin inhibitors rejection prophylaxis represent current best practice pending publication long-term results using newer agents.stronguse tacrolimus first-line calcineurin inhibitor due higher efficacy.strongmonitor blood-levels cyclosporine tacrolimus allow appropriate dose adjustment calcineurin inhibitors.strong